| 1 | Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) | 3件: Ocrelizumab Ocrelizumab, Ofatumumab (Ofatumumabum), Rituximab | 3件: Rituximab
Rituximab
,
Ocrelizumab
,
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 2 | ArzerraProduct Name: ofatumumabProduct Code: OMB157Pharmaceutical Form: Solution for injection in pre-filled syringeINN or Proposed INN: OFATUMUMABCAS Number: 679818-59-8Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 50-Pharmaceutical form of the placebo: Solution for injection in pre-filled syringeRoute of administration of the placebo: Subcutaneous useTrade Name: KesimptaProduct Name: ofatumumabProduct Code: OMB157Pharmaceutical Form: Solution for injection in pre-filled penINN or Proposed INN: OFATUMUMABCAS Number: 679818-59-8Concentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 50- | - | - | - | - | 1件: 13 13 💬
|
| 3 | Combination Product: ofatumumab with AI | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 4 | Combination Product: ofatumumab with PRF | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 5 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | 12件: Acetate Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab (Ofatumumabum), Ponesimod, Rituximab, Teriflunomide | 13件: Cladribine
Cladribine
,
Alemtuzumab
,
Rituximab
,
Dimethyl fumarate
,
Fingolimod hydrochloride
,
Glatiramer acetate
,
Ocrelizumab
,
Natalizumab
,
Ofatumumab
(Ofatumumab),
Fingolimod
,
Teriflunomide
,
Ponesimod
,
Fingolimod lauryl sulfate
💬
| 26件: DHODH DHODH, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬
| 58件: Allograft rejection Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 13 13 💬
|
| 6 | Ofatumumab | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 6件: 11 11, 13, 35, 46, 222, 223 💬
|
| 7 | Ofatumumab 100 | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 8 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 9 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 10 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 11 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 12 | Ofatumumab 700 | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 13 | Ofatumumab approved dose | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 14 | Ofatumumab new dose | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
| 15 | Ofatumumab subcutaneous injection | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 13 13, 35 💬
|
| 16 | Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq | 8件: Alemtuzumab Alemtuzumab, Cladribine, Hyaluronidase, Natalizumab, Ocrelizumab, Ofatumumab (Ofatumumabum), Rituximab, Ublituximab | 10件: Cladribine
Cladribine
,
Alemtuzumab
,
Rituximab
,
Hyaluronidase
,
Hyaluronidase
,
Ocrelizumab
,
Hyaluronidase
,
Natalizumab
,
Ofatumumab
(Ofatumumab),
Ublituximab
💬
| 3件: ITGA4 ITGA4, MS4A1, RRM1 💬
| 21件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬
|
| 17 | Other: Ofatumumab | 1件: Ofatumumab Ofatumumab (Ofatumumabum) | 1件: Ofatumumab
Ofatumumab
(Ofatumumab) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|